Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about the timeline for Kintor's phase 3 trials for GT20029 and the potential release of the product in three years. It also mentions treatments like Minoxidil, finasteride, and RU58841.

A 21-year-old shares their one-year progress using finasteride for hair loss, experiencing initial shedding but eventual regrowth, especially on the crown. They consider switching to dutasteride due to continued hair loss at the front temple and mid-scalp areas.

There are no updates on GT20029, and concerns about its safety and effectiveness remain. The phase III trial has not started, and there are no new studies or data releases.

The user is considering reducing their finasteride dose from 2.5mg to 1.25mg to make the supply last longer and is concerned about potential changes in results. They have been using the 2.5mg dose for four months.

The user has been using 5% minoxidil and finasteride for a year and recently noticed three new hairs, but other baby hairs aren't growing. They are considering switching to only minoxidil.

A user shared their hair regrowth progress using 1 mg finasteride, 10% minoxidil with 0.1% finasteride solution, and derma rolling, noting significant improvement in crown density over five months. They experienced initial shedding but reported no side effects from finasteride and plan to continue treatment for 10-11 months before deciding on future steps.

The conversation is about seeking information on GT20029 from Kintor Pharmaceutical as a potential hair loss cure and inquiring about experiences with CosmeaRNA.

A user's hair regrowth journey involved a hair transplant and using RU58841, finasteride, and minoxidil, with side effects managed by other medications.

A 29-year-old shared their hair recovery progress using a liposomal topical finasteride/minoxidil solution, LLLT helmet, and vitamins, noting that transplants were only on the hairline. They highlighted the effectiveness of their regimen and addressed skepticism with photos.

The user has been using finasteride, minoxidil, and a derma stamp for 3 months with significant improvement. They are now adding ketoconazole to their routine.

The conversation discusses using 2-deoxy-d-ribose (2DDR) for hair regrowth, with users sharing mixed experiences and side effects like hair loss in new areas and increased anxiety. The original poster plans to continue testing and comparing it to minoxidil, noting potential instability in 2DDR formulations.

Experimenting with trestolone as a treatment for hair loss in an attempt to avoid DHT-related treatments such as finasteride and dutasteride, and discussing the potential effects of its receptor selectivity on the androgen receptors in the scalp.

Someone switched from topical minoxidil to oral minoxidil and found it more effective and convenient, reporting improvements in hair, eyebrows, eyelashes, and beard without scalp issues. They are seeking long-term experiences from others who made the same switch.

User switched from Fin to Dut for better hair loss results, using 0.5mg Dut and 1ml Min daily. Some discuss potential side effects and benefits of Dut compared to Fin.

A user switched from RU58841 to Pyrilutamide for hair loss treatment after experiencing side effects and continued hair shedding with RU. They are now losing hair faster with Pyrilutamide and questioning if they should revert to RU58841.

Clascoterone 5% solution is discussed as a potential new treatment for hair loss, offering an alternative for those who can't use finasteride or need additional options beyond minoxidil. Concerns about cost, effectiveness, and safety compared to existing treatments like RU58841 and finasteride are highlighted.

Using a combination of Stemoxydine, minoxidil, dutasteride, and keto shampoo to achieve extreme hair and beard growth. The user has experienced positive results with terminal hairs at the hairline and an increase in density to their stubble after several weeks of use.

The user has been using oral finasteride and minoxidil for 1.5 years with some crown improvement but still experiences thin hair and a receding hairline. They are considering switching to dutasteride for potentially better results, while others suggest adding topical minoxidil back into the routine.

The post and conversation are about a user's experience with hair loss treatments, specifically switching from finasteride to dutasteride. The user experienced significant hair shedding after the switch, with others suggesting patience, noting similar experiences, or questioning the user's decision and medical consultation.

The conversation is about hair loss treatments, focusing on finasteride and considering a switch to dutasteride due to hairline recession. Users suggest trying minoxidil or dermarolling before switching, while others recommend dutasteride for more aggressive hair loss.

The conversation discusses promising hair cloning research seeking commercialization partners. Cultured hairs formed with pigment, indicating positive progress.

The conclusion of the conversation is that the user has decided to embrace their hair loss and has buzzed their head. They plan to continue their current hair loss treatments until they run out of stock. They also mention having dandruff and will continue medication for that.

Breezula shows promise in stabilizing hair loss and potentially promoting regrowth at the one-year mark, offering hope for those who can't tolerate 5AR inhibitors. Its local targeting of androgen receptors could be a significant advancement if it avoids systemic side effects.

The conversation discusses hair regrowth after 7 months of treatment, with the recent addition of tretinoin 0.05%. The treatment routine remained the same as before, except for this new addition.

Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.

The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.

The user noticed hair regrowth after 4 years of hair loss, coinciding with lifestyle improvements like quitting smoking, exercising, and a better diet. They are curious if dormant follicles can recover under improved conditions.

A user switched from finasteride to dutasteride and experienced continuous shedding but is now seeing some regrowth. Others shared similar experiences, noting that shedding can continue but hair often improves over time with dutasteride.

Eirion Therapeutics is recruiting for phase 1 of ET-02 in Texas, which showed promising hair growth results in non-clinical studies. ET-02 demonstrated significantly more hair growth compared to Minoxidil.

SCUBE3 clinical trials for hair loss treatment to start this year. Treatment may involve regular, painless scalp injections to maintain hair growth.